Study shows DHPS enzyme controls macrophage maturation across multiple organs
A new study led by researchers at the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns…
Web-based cytometry atlas reveals immune signatures across pancreatic cancer treatments
Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of vaccines and…
Preclinical study reveals potential new treatment for severe liver fibrosis
Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis – a dangerous, disease-induced build-up of…
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
BioXcel Therapeutics Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation…
Longevity therapeutics market to double by 2033
Global longevity therapeutics market projected to hit US$43.72b by 2033, as supplements and antiaging solutions move from niche…
Researchers discover the enzyme responsible for chromothripsis in cancer
University of California San Diego researchers have discovered the enzyme responsible for chromothripsis, a process in which a…
Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve…
Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows…
Global Virus Network outlines priorities as Marburg virus emerges in Ethiopia
The Global Virus Network (GVN), a coalition of leading human and animal virologists in more than 40 countries…
Experimental drug engasertib shows promise for treating inherited bleeding disorder
Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting 1 in 3,800 persons.…
2 No-Brainer Healthcare Stocks to Buy Now
Pfizer’s acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach…
New insights into glioblastoma survival linked to brain fluid dynamics
Glioblastoma-the most aggressive form of brain cancer-remains one of medicine’s biggest challenges. Despite surgery, radiotherapy, and chemotherapy, most…